NASDAQ:STIMNeuronetics Stock Price, Forecast & News

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, STIM stock has decreased by 9.7% and is now trading at $1.87. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neuronetics.

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Neuronetics.

Neuronetics Inc (NASDAQ:STIM) issued its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.13. The firm had revenue of $11.48 million for the quarter. Neuronetics had a negative net margin of 55.58% and a negative return on equity of 68.77%. View Neuronetics' earnings history.

Neuronetics issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.8-12 million, compared to the consensus revenue estimate of $13.77 million.

4 analysts have issued twelve-month target prices for Neuronetics' shares. Their forecasts range from $4.00 to $6.00. On average, they expect Neuronetics' share price to reach $5.33 in the next year. This suggests a possible upside of 185.2% from the stock's current price. View analysts' price targets for Neuronetics.

News coverage about STIM stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neuronetics earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Neuronetics.

Neuronetics saw a increase in short interest in June. As of June 30th, there was short interest totaling 825,200 shares, an increase of 13.3% from the June 15th total of 728,400 shares. Based on an average daily volume of 546,500 shares, the short-interest ratio is presently 1.5 days. Approximately 7.7% of the company's stock are short sold. View Neuronetics' Current Options Chain.

Some companies that are related to Neuronetics include Soliton (SOLY), Restoration Robotics (HAIR), BeyondAirInc . (XAIR), Venus Concept (VERO), Spectral Medical (EDTXF), PAVmed (PAVM), SANUWAVE Health (SNWV), Nephros (NEPH), AIT Therapeutics (AITB), Pro-Dex (PDEX), BRAINSWAY LTD/S (BWAY), Nephros (NEPHD), Titan Medical (TMDI), Sensus Healthcare (SRTS) and Motus GI (MOTS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS), Nokia Oyj (NOK), Novavax (NVAX) and Onconova Therapeutics (ONTX).

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STIM stock can currently be purchased for approximately $1.87.

Neuronetics has a market capitalization of $35.03 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe.

The official website for Neuronetics is www.neurostar.com.

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]